Many patients’ and consumers’ organizations accept drug industry funding to support their activities. As drug companies and patient groups move closer, disclosure become essential for transparency, and the internet could be a useful means of making sponsorship information accessible to the public. This survey aims to assess the transparency of a large group of Italian patient and consumer groups and a group of pharmaceutical companies, focusing on their websites.Patient and consumer groups were selected from those stated to be sponsored by a group of pharmaceutical companies on their websites. The websites were examined using two forms with principal (name of drug companies providing funds, amount of funding) and secondary indicators of tra...
Relationships between health professionals and pharmaceutical manufacturers can unduly influence cli...
Objective: To investigate pharmaceutical or medical device industry funding of patient groups. Desig...
OBJECTIVE: To analyse voluntary payment reports of pharmaceutical companies to German healthcare pro...
Many patients’ and consumers’ organizations accept drug industry funding to support their activities...
Background: Many patients ’ and consumers ’ organizations accept drug industry funding to support th...
∧<p>March 2010.</p>*<p>Reference to the activities funded varied among drug companies, from detailed...
Abstract Background Patient organisations may be exposed to conflicts of interest and undue influenc...
Background: The transparency criteria adopted by the European Medicines Agency require eligible pati...
Patient organisations contribute to many areas of pharmaceutical policy. In developing their organis...
*<p>organizations not included in other categories: e.g. growth hormone deficiency, psoriasis, infla...
Background: The transparency criteria adopted by the European Medicines Agency require eligible pati...
Pharmaceutical companies regularly fund patient organisations. It is important for patient organisat...
Transparency has become one of the primary themes in health care reform efforts in the United States...
The European pharmaceutical industry uses the alleged efficacy of self-regulation to question the ne...
Objectives: To analyse the section of Disclosure UK that pertains to healthcare professionals (HCPs)...
Relationships between health professionals and pharmaceutical manufacturers can unduly influence cli...
Objective: To investigate pharmaceutical or medical device industry funding of patient groups. Desig...
OBJECTIVE: To analyse voluntary payment reports of pharmaceutical companies to German healthcare pro...
Many patients’ and consumers’ organizations accept drug industry funding to support their activities...
Background: Many patients ’ and consumers ’ organizations accept drug industry funding to support th...
∧<p>March 2010.</p>*<p>Reference to the activities funded varied among drug companies, from detailed...
Abstract Background Patient organisations may be exposed to conflicts of interest and undue influenc...
Background: The transparency criteria adopted by the European Medicines Agency require eligible pati...
Patient organisations contribute to many areas of pharmaceutical policy. In developing their organis...
*<p>organizations not included in other categories: e.g. growth hormone deficiency, psoriasis, infla...
Background: The transparency criteria adopted by the European Medicines Agency require eligible pati...
Pharmaceutical companies regularly fund patient organisations. It is important for patient organisat...
Transparency has become one of the primary themes in health care reform efforts in the United States...
The European pharmaceutical industry uses the alleged efficacy of self-regulation to question the ne...
Objectives: To analyse the section of Disclosure UK that pertains to healthcare professionals (HCPs)...
Relationships between health professionals and pharmaceutical manufacturers can unduly influence cli...
Objective: To investigate pharmaceutical or medical device industry funding of patient groups. Desig...
OBJECTIVE: To analyse voluntary payment reports of pharmaceutical companies to German healthcare pro...